来自瘦素临床研究的证据:当前和未来人类临床应用
Nikolaos Perakakis1, Christos S Mantzoros2
1Division of Metabolic and Vascular Medicine, Department of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany; Paul Langerhans Institute Dresden (PLID), Helmholtz Center Munich, University Hospital and Faculty of Medicine, TU Dresden, Dresden, Germany; German Center for Diabetes Research (DZD e.V.), Neuherberg, Germany.
Metabolism: clinical and experimental
|November 3, 2024
概括
瘦素替代疗法有效地治疗瘦素缺乏的代谢和内分泌问题. 然而,瘦素治疗对于肥胖等瘦素过多的疾病没有代谢益处.
科学领域:
- 内分泌学 在内分泌学.
- 代谢过程中的代谢.
- 免疫学 免疫学 免疫学
背景情况:
- 丁是一种由脂肪组织分泌的关键激素,调节人类众多生理功能.
- 了解瘦素的作用对于代谢,内分泌和免疫系统的健康至关重要.
研究的目的:
- 审查关于在勒缺乏和过多的情况下给予勒的人类研究.
- 为了将人类发现与临床前模型进行比较,并阐明丁的治疗潜力.
主要方法:
- 人类研究的系统审查,涉及莱普的管理.
- 在各种缺乏状态 (禁食,REDS,CLD,脂质变) 和过量状态 (肥胖,2型糖尿病) 中分析丁的作用.
主要成果:
- 在缺乏状态下,瘦素替代可以减少体重,脂肪量,改善高甘油三血症,胰岛素耐药性,肝硬化,神经内分泌功能,免疫细胞群和骨健康.
- 在过度状态 (肥胖,2型糖尿病) 中,丁治疗没有改善代谢异常.
结论:
- 瘦素治疗对瘦素缺乏有效,但对瘦素过多的疾病 (如常见的肥胖症) 不有效.
- 克服肥胖症中瘦素耐药性的策略需要进一步的人类临床试验.
相关概念视频
01:30Regulation of Food Intake
195
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
195
01:24Obesity
383
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
383
01:24Glucagon-like Receptor Agonists
300
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
300